lecture time

december 23, 2024 9:30-12:30

lecture location

academic lecture hall on the third floor of building 1, jinfeng laboratory

lecture topic 1: omics technology and tumor metabolic remodeling

introduction to the speaker

hu zeping, researcher at the school of pharmacy, tsinghua university, permanent associate professor, pi of the joint life center, and was selected as a high-level distinguished professor of the ministry of education. he presides over national-level scientific research projects such as original exploration projects, key projects, major research plan key projects and integrated projects of the national foundation of china, and undertakes new drug research and development cooperation projects funded by leading international pharmaceutical companies.

lecture introduction

professor hu's research group develops new metabolomics and multi-omics integration technologies, combines bioinformatics and ai technology, and uses methods such as cellular, molecular and metabolic biology to deeply explore the microenvironmental metabolic interactions and regulation of tumors and cardiovascular diseases. mechanism, providing new ideas and potential new drug targets for its treatment.

lecture topic 2: progress in individualized treatment of liver cancer

introduction to the speaker

chen lei, eastern hepatobiliary surgery hospital of naval medical university, outstanding youth and outstanding youth of the national foundation of china, young yangtze river scholar of the ministry of education, and outstanding academic leader in shanghai. he has long been engaged in research on the occurrence and development of liver cancer and the molecular mechanism of drug resistance. he has published more than 80 sci papers, with a total of more than 4,300 citations, and 6 papers were selected as esi highly cited papers.

lecture introduction

hepatocellular carcinoma (hcc) is the fourth most common cause of cancer-related mortality worldwide. metabolic reprogramming occurs widely in cancer and is considered one of the hallmarks of malignant tumors. the mechanisms of metabolic reprogramming of liver cancer cells are complex and have not yet been fully understood. professor chen's research group defined cps1-deficient liver cancer subtypes through big data mining, used mass spectrometry to reveal that fatty acid oxidation (fao) metabolism in liver cancer cells is active, and then promotes tumorigenesis by activating the transcription factor foxm1, and used organoids to propose targeted therapies for this type of liver cancer. new strategies for targeted treatment of subtypes.